Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Seattle Genetics (SGEN) -- Ignore unavailable to you. Want to Upgrade?

To: Miljenko Zuanic who wrote (148)	12/3/2016 10:10:43 PM
From: Miljenko Zuanic	Read Replies (1) \| Respond to of 161

(7+3) + CD33 in frontline AML for younger patients: Of 42 patients evaluable for response, 32 patients (76 percent) achieved a complete remission (CR) or complete remission with incomplete platelet or neutrophil recovery (CRi). Ninety-four percent of the remissions (CR or CRi) occurred with one cycle of therapy. Twenty-five of the 32 patients (78 percent) who achieved remission were negative for minimal residual disease (MRD). MRD-negative remission post-induction is generally correlated with reduced rates of relapse and improved overall survival. http://finance.yahoo.com/news/seattle-genetics-presents-phase-1b-200000392.html Very attractive so far, if hold in P2, breakthrough is very likely.